Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
Rhea-AI Summary
Recursion (Nasdaq: RXRX) will report fourth quarter and full year 2025 business updates and financial results on Wednesday, February 25, 2026, before market open. The company will host a public (L)earnings call at 8:00 AM ET / 6:00 AM MT / 1:00 PM GMT.
The live stream will be broadcast on Recursion’s X, LinkedIn, and YouTube accounts, and investors may submit questions in advance via the company’s online form.
Positive
- None.
Negative
- None.
News Market Reaction – RXRX
On the day this news was published, RXRX gained 2.02%, reflecting a moderate positive market reaction. Argus tracked a peak move of +23.5% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $38M to the company's valuation, bringing the market cap to $1.94B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RXRX was down 0.86% while momentum peer IDYA was up 3.67%, and listed sector peers (GLPG, APGE, ARQT, IDYA, TVTX) all showed positive price changes, indicating stock-specific pressure rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Inducement RSU grants | Negative | -3.5% | New employee inducement RSUs under 2024 plan, adding equity-based compensation. |
| Jan 06 | Conference participation | Positive | +4.1% | Planned presentations at J.P. Morgan and Needham healthcare conferences. |
| Dec 08 | Clinical data update | Positive | +2.3% | Positive Phase 1b/2 TUPELO REC-4881 data showing reduced polyp burden in FAP. |
| Dec 01 | Clinical webinar notice | Neutral | -5.8% | Announcement of upcoming webinar for REC-4881 TUPELO trial data readout. |
| Nov 05 | Earnings and update | Negative | -0.8% | Q3 2025 results with lower revenue, high R&D spend, and net loss disclosure. |
Recent news reactions mostly aligned with the tone of announcements, with only one notable divergence on a clinical webinar notice.
Over the last few months, Recursion’s news flow included inducement equity awards on Feb 12, 2026, multiple conference appearances in January 2026, and positive Phase 1b/2 REC-4881 data in FAP on Dec 8, 2025. An earlier webinar announcement for that trial on Dec 1, 2025 saw a negative reaction. Q3 2025 earnings on Nov 5, 2025 highlighted substantial cash balances and partner milestones. Today’s earnings date announcement continues the pattern of scheduled investor communications and guidance updates.
Market Pulse Summary
This announcement schedules Recursion’s Q4 and full-year 2025 business update and earnings release for February 25, 2026, with a public call at 8:00 am ET. It continues a pattern of regular investor communications following prior clinical data updates and conference appearances. Investors may focus on revenue trends, R&D spending, cash runway, and pipeline progress compared with the Q3 2025 snapshot when evaluating the forthcoming results.
AI-generated analysis. Not financial advice.
Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT
Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the open of the financial markets.
Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFmikcu6.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, and the Oxford area. Learn more at www.recursion.com, or connect on X and LinkedIn.
Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the timing of the filing of quarterly earnings; the occurrence and timing of an investor call; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.
Media Contact media@recursion.com Investor Contact investor@recursion.com